686775-20-2

Basic information

• Product Name: 5,8,13,17,22,25-Hexaoxanonacosanedioic acid, 15-[3-carboxy-1-oxopropoxy]-7,23-bis[[1,4-dioxo-4-(phenylmethoxy)but oxy]methyl]-4,9,12,18,21,26-hexaoxo-, 1,29-bis(phenylmethyl) ester
• CAS NO: 686775-20-2
• Molecular Formula: C65H72O28
• Molecular Weight: 1301.27
• Mol File: 686775-20-2.mol

Chemical Properties

• CAS DataBase Reference: 5,8,13,17,22,25-Hexaoxanonacosanedioic acid, 15-[3-carboxy-1-oxopropoxy]-7,23-bis[[1,4-dioxo-4-(phenylmethoxy)but oxy]methyl]-4,9,12,18,21,26-hexaoxo-, 1,29-bis(phenylmethyl) ester(CAS DataBase Reference)
• NIST Chemistry Reference: 5,8,13,17,22,25-Hexaoxanonacosanedioic acid, 15-[3-carboxy-1-oxopropoxy]-7,23-bis[[1,4-dioxo-4-(phenylmethoxy)but oxy]methyl]-4,9,12,18,21,26-hexaoxo-, 1,29-bis(phenylmethyl) ester(686775-20-2)
• EPA Substance Registry System: 5,8,13,17,22,25-Hexaoxanonacosanedioic acid, 15-[3-carboxy-1-oxopropoxy]-7,23-bis[[1,4-dioxo-4-(phenylmethoxy)but oxy]methyl]-4,9,12,18,21,26-hexaoxo-, 1,29-bis(phenylmethyl) ester(686775-20-2)

Safety Data

• Hazardous Substances Data: 686775-20-2(Hazardous Substances Data)

Relevant articles and documents

Synthesis and aqueous aggregation properties of amphiphilic surface-block dendrimers

(Chemical Equation Presented) A family of dendritic amphiphiles were synthesized from the natural metabolites of glycerol, succinic acid, and myristic acid. The surfaces of these dendrimers display different numbers of alkyl chains and carboxylic acids, v

Anionic amphiphilic dendrimers as antibacterial agents

An anionic amphiphilic dendrimer is reported that possesses increased cytotoxicological potency against prokaryotic cells compared to eukaryotic cells. The half-maximal effective concentration (EC50) for the dendrimer against Bacillus subtilis, a Gram-positive bacterial strain, was measured to be 4.1 × 10-5 M, while that against human umbilical vein endothelial cells (HUVEC) was more than 36× greater at a value of 1.5 × 10-3 M. EC50 ratios for two commercial amphiphiles, sodium dodecyl sulfate (SDS) and Triton X-100, in addition to a similar synthesized dendritic structure were at most only 3.8× greater. Furthermore, the observed EC50 values appear to be correlated to the critical aggregation constant (CAC) in solution suggesting a mechanism of action for these anionic amphiphilic dendrimers related to their supramolecular structures. Copyright

LOW-SWELLING HYDROGEL SEALANTS FOR WOUND REPAIR

One aspect of the present invention relates to a sealant comprising dendrimeric macromolecules that form a hydrogel. In certain instances, the sealants of the invention comprise a hydrogel that swells less than about 400 wt% upon hydration. In certain instances, the sealants of the present invention further comprise a pharmaceutical agent, such as an antibiotic, antimicrobial agent, or antiinflammatory agent. The sealants of the present invention may be used to treat a wound on a patient that is topical or in vivo. In addition, the sealants of the present invention can act as a barrier to bacteria and other organisms. Another aspect of the present invention relates to a method of sealing a wound on a patient comprising the steps of applying an effective amount of a dendrimeric compound to a wound on a patient and treating the dendrimeric compound with a polymerization agent. Another aspect of the present invention relates to a method of sealing a wound on a patient comprising the steps of treating a dendrimeric compound with a polymerization agent to form a repair agent, and applying the repair agent to a wound on a patient. Another aspect of the present invention relates to a kit for sealing a wound comprising a polymerizable dendrimeric compound that forms a hydrogel and a system for delivering the polymerizable dendrimeric compound to a wound on a patient.

DENTRITIC POLYMERS, CROSSLINKED GELS, AND THEIR USES IN ORTHOPEDIC APPLICATIONS

The present invention provides compositions, kits, and methods for repairing cartilaginous tissue. Certain methods of the invention utilize dendritic macromolecules formed by treating a dendritic compound with light or a linking compound. In certain instances, the dendritic compounds have a lysine, cysteine, isocysteine residue or other nucleophilic group attached to their peripheries. Addition of a compound containing two or more electrophilic groups, such as aldehydes, activated esters, or acrylates, to the lysine-capped, cysteine-capped, or isocysteine-capped dendrimers produces a polymeric compound that can repair a cartilage defect.

DENDRITIC POLYMERS, CROSSLINKED GELS, AND THEIR USES AS OPHTHALMIC SEALANTS AND LENSES

The present invention provides compositions and methods for sealing a wound and preparing a lens. The methods of the invention utilize dendritic macromolecules formed by treating a dendritic compound with light or a linking compound. In certain instances, the dendritic compounds have a lysine-, cysteine-, isocysteine-residue or other nucleophilic group attached to the periphery of the dendrimer: Addition of a compound containing two or more electrophilic groups such as aldehydes, activated esters, or acrylates to the lysine-, cysteine-, or isocysteine-capped dendrimers produces a polymeric compound that can form a seal or a lens. Another aspect of the invention relates to a method of treating disease using the pharmaceutical compositions of the invention. Other aspects of the invention relate to kits for sealing a wound or preparing a lens, delivery devices, and methods for controlling the polymerization of a hydrogel system.